Proton pump inhibitors (PPI) vs control: Number of participants with worsening scores in corporal atrophy
Proton pump inhibitor showed no clear difference in number of participants with worsening scores in corporal atrophy compared with control (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Proton pump inhibitor vs control Number of participants with worsening scores in corporal atrophy · people with pre‐malignant lesions Proton pump inhibitor showed no clear difference in number of participants with worsening scores in corporal atrophy compared with control (low certainty). Long‐term proton pump inhibitor (PPI) use and the development of gastric pre‐malignant lesions (2014) · Cochrane Headline outcomes only | OR 1.5 [0.59, 3.8] | 4 studies · 1070 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Long‐term proton pump inhibitor (PPI) use and the development of gastric pre‐malignant lesions 2014 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.